PALISADE BIO, INC.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

PALI$1.13-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Preferred Stock · Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares · Amount
Balance, March 31, 2025	200,000	$2	4,396,646	$43	$143,460	$(138,174)	$5,331
Net loss	—	—	—	—	—	(2,784)	(2,784)
Stock-based compensation expense and related charges	—	—	—	—	69	—	69
Issuance of common stock under Employee Stock Purchase Plan	—	—	4,601	—	3	—	3
Issuance of common stock in connection with exercise of warrants	—	—	399,000	5	(4)	—	1
Balance, June 30, 2025	200,000	$2	4,800,247	$48	$143,528	$(140,958)	$2,620

Preferred Stock · Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares · Amount
Balance, March 31, 2024	200,000	$2	851,302	$8	$135,087	$(125,033)	$10,064
Net loss	—	—	—	—	—	(4,080)	(4,080)
Stock-based compensation expense and related charges	—	—	—	—	362	—	362
Issuance of common stock to vendors	—	—	15,603	—	73	—	73
Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability	—	—	12,084	—	(25)	—	(25)
Issuance of common stock in connection under Employee Stock Purchase Plan	—	—	2,256	—	11	—	11
Issuance of common stock and warrants in May 2024 Offering, net of issuance costs of $705	—	—	85,100	1	3,543	—	3,544
Balance, June 30, 2024	200,000	$2	966,345	$9	$139,051	$(129,113)	$9,949

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Preferred Stock · Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares · Amount
Balance, December 31, 2024	200,000	$2	2,768,646	$27	$143,407	$(135,944)	$7,492
Net loss	—	—	—	—	—	(5,014)	(5,014)
Stock-based compensation expense and related charges	—	—	—	—	138	—	138
Issuance of common stock under Employee Stock Purchase Plan	—	—	4,601	—	3	—	3
Issuance of common stock in connection with exercise of warrants	—	—	2,027,000	21	(20)	—	1
Balance, June 30, 2025	200,000	$2	4,800,247	$48	$143,528	$(140,958)	$2,620

Preferred Stock · Common Stock · AdditionalPaid-inCapital* · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares* · Amount*
Balance, December 31, 2023	200,000	$2	618,056	$6	$132,811	$(121,506)	$11,313
Net loss	—	—	—	—	—	(7,607)	(7,607)
Stock-based compensation expense and related charges	—	—	—	—	480	—	480
Issuance of common stock to vendors	—	—	15,603	—	73	—	73
Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability	—	—	17,270	—	(25)	—	(25)
Issuance of common stock in connection under Employee Stock Purchase Plan	—	—	2,256	—	11	—	11
Issuance of common stock in connection with warrant inducement, net of issuance costs of $2,412 (Note 5)	—	—	228,162	2	2,158	—	2,160
Issuance of common stock and warrants in May 2024 Offering, net of issuance costs of $705	—	—	85,100	1	3,543	—	3,544
Reverse stock split fractional share settlement	—	—	(102)	—	—	—	—
Balance, June 30, 2024	200,000	$2	966,345	$9	$139,051	$(129,113)	$9,949

(*)Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.

Condensed Consolidated Stateme

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.